tearxaban

Tearxaban is an **oral, small molecule anticoagulant** in development as a **direct, selective inhibitor of coagulation factor Xa**. The drug is being developed to address unmet needs in the prevention and treatment of thrombotic cardiovascular disorders, including deep venous thrombosis, thromboembolism, and stroke in patients with atrial fibrillation associated with acute coronary syndrome. The active pharmaceutical ingredient was originally developed by F. Hoffmann-La Roche. Tearxaban is promoted as offering rapid onset and cessation of action, minimal drug-drug interactions, no need for laboratory INR monitoring, and high selectivity for its target[4].

Brand names

tearxaban

Other names

TeaRx